UK markets closed

Revance Therapeutics, Inc. (RVNC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.8200-0.1500 (-5.05%)
At close: 04:00PM EDT
2.8300 +0.01 (+0.35%)
After hours: 07:07PM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Cash flows from operating activities
Net income
-317,345
-323,986
-356,422
-281,310
-282,089
-
Depreciation & amortisation
9,056
13,693
39,146
19,853
10,250
-
Deferred income taxes
-
-
0
0
-2,720
0
Stock-based compensation
43,721
47,813
52,340
43,434
36,453
-
Change in working capital
-38,528
-43,882
665
-4,774
39,972
-
Accounts receivable
-14,514
-16,338
-7,990
-1,519
-1,736
-
Inventory
-9,384
-14,910
-6,008
-4,278
-5,876
-
Accounts payable
-5,030
6,900
-5,448
-1,824
4,425
-
Other working capital
-224,204
-223,461
-196,758
-231,913
-182,718
-
Other non-cash items
2,949
3,043
3,110
1,170
21,055
-
Net cash provided by operating activities
-213,014
-216,575
-193,548
-221,538
-178,502
-
Cash flows from investing activities
Investments in property, plant and equipment
-11,190
-6,886
-3,210
-10,375
-4,216
-
Acquisitions, net
-
-
0
0
-818
0
Purchases of investments
-307,664
-263,923
-347,966
-183,590
-259,304
-
Sales/maturities of investments
306,452
385,432
232,178
172,000
276,469
-
Other investing activities
-
-4,883
-19,800
-7,700
-
-
Net cash used for investing activities
-17,285
109,740
-138,798
-29,665
12,131
-
Cash flows from financing activities
Debt repayment
0
-18,255
-11,097
0
0
-
Common stock issued
197,809
100,183
248,014
21,706
83,948
-
Other financing activities
-5,926
-9,065
-8,193
-8,525
-46,856
-
Net cash used provided by (used for) financing activities
226,130
136,567
331,694
29,869
331,484
-
Net change in cash
-4,169
29,732
-652
-221,334
165,113
-
Cash at beginning of period
144,098
115,017
115,669
337,003
171,890
-
Cash at end of period
139,929
144,749
115,017
115,669
337,003
-
Free cash flow
Operating cash flow
-213,014
-216,575
-193,548
-221,538
-178,502
-
Capital expenditure
-11,190
-6,886
-3,210
-10,375
-4,216
-
Free cash flow
-224,204
-223,461
-196,758
-231,913
-182,718
-